Back
ESC Premium Access

Comparative safety and effectiveness of standard doses of apixaban versus dabigatran, rivaroxaban, and VKAs in non-valvular atrial fibrillation patients in France: the NAXOS study

Session: Identifying and managing complications of atrial fibrillation
Topic: Oral Anticoagulation
Speaker: Professor N. Danchin (Paris, FR)
Event: ESC Congress 2019

Congress Presentation

Add to my library

Like

About the speaker

Professor Nicolas Danchin

Saint Joseph Hospital, Paris (France)
18 presentations
1 follower

5 more presentations in this session

Stroke severity and subsequent mortality are worse with atrial fibrillation than in patients without atrial fibrillation

Speaker: Ms N. Vinding (Copenhagen, DK)

Access
Abstract
Slides
Like
Thumbnail

Resumption of anticoagulant treatment in patients with atrial fibrillation following gastrointestinal bleeding: a nationwide cohort study

Speaker: Miss D. Rajan (Copenhagen, DK)

Access
Abstract
Slides
Like
Thumbnail

ETNA-AF Europe: First 1-year follow-up snapshot analysis of more than 7,500 AF patients treated with edoxaban in routine clinical practice

Speaker: Professor R. De Caterina (Pisa, IT)

Access
Abstract
Slides
Like
Thumbnail

Left atrial dimension and risk of cardiovascular outcomes in patients with and without atrial fibrillation: a systematic review and meta-analysis

Speaker: Doctor P. Meyre (Basel, CH)

Access
Abstract
Slides
Like
Thumbnail

Right atrial low voltage zone as a novel predictor of sinus node dysfunction in patients with non-paroxysmal atrial fibrillation

Speaker: Doctor T. Kondo (Hiroshima, JP)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Identifying and managing complications of atrial fibrillation

Speakers: Professor N. Danchin, Ms N. Vinding, Miss D. Rajan, Professor R. De Caterina, Doctor P. Meyre...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources